{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:24Z","timestamp":1792096764031,"version":"4.4.0"},"reference-count":175,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jconrel.2014.04.009","type":"journal-article","created":{"date-parts":[[2014,4,13]],"date-time":"2014-04-13T09:31:46Z","timestamp":1397381506000},"page":"36-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Nanostructured drug delivery for better management of tuberculosis"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-2974","authenticated-orcid":false,"given":"Indu Pal","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2014.04.009_bb0005","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1038\/nm1221","article-title":"Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis","volume":"11","author":"Kaufmann","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/156802608783955629","article-title":"Developments on drug delivery systems for the treatment of mycobacterial infections","volume":"8","author":"Gaspar","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1055\/s-0028-1085702","article-title":"Epidemiology and treatment of multidrug resistant tuberculosis","volume":"29","author":"Mitnick","year":"2008","journal-title":"Semin. Respir. Care Med."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.addr.2009.11.015","article-title":"Nanotechnology diagnostics for infectious diseases prevalent in developing countries","volume":"62","author":"Hauck","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0025","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(03)14333-4","article-title":"Tuberculosis","volume":"362","author":"Frieden","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1465-9921-7-118","article-title":"Tuberculosis chemotherapy: current drug delivery approaches","volume":"7","author":"du Toit","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0035","author":"WHO"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0040","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1099\/mic.0.049213-0","article-title":"Characterization of the KstR-dependent promoter of the gene for the first step of the cholesterol degradative pathway","volume":"157","author":"Uh\u00eda","year":"2011","journal-title":"Microbiology"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0050","first-page":"1436","article-title":"Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates","volume":"14","author":"Sun","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0055","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrmicro1419","article-title":"Advances in tuberculosis vaccine strategies","volume":"4","author":"Skeiky","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bmj.324.7341.802","article-title":"Management of co-infection with HIV and TB: improving tuberculosis control programmes and access to highly active antiretroviral treatment is crucial","volume":"324","author":"Colebunders","year":"2002","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0065","first-page":"550","article-title":"HIV-TB co-infection: epidemiology, diagnosis and management","volume":"212","author":"Sharma","year":"2005","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0070","author":"WHO"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0075","first-page":"857","article-title":"Treatment of tuberculosis: present status and future prospects","volume":"83","author":"Onyebujoh","year":"2005","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0080","series-title":"3rd Geneva World Health Organization, 2003","article-title":"Treatment of tuberculosis: guidelines for national programmes","author":"WHO","year":"2003"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0085","first-page":"61","article-title":"The rationale for recommending fixed dose combination tablets for treatment of tuberculosis","volume":"79","author":"Blomberg","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0090","first-page":"S301","article-title":"Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption","volume":"3","author":"Ellard","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"2","key":"10.1016\/j.jconrel.2014.04.009_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1472-9792(08)70011-8","article-title":"Isoniazid","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0100","first-page":"285","article-title":"Antibiotic treatment of tuberculosis: old problems, new solutions","volume":"3","author":"Jain","year":"2008","journal-title":"Microbe"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0167-4889(93)90137-E","article-title":"Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum","volume":"1179","author":"Moghimi","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0110","first-page":"467","volume":"vol. 5","author":"Gallo","year":"1976"},{"issue":"2","key":"10.1016\/j.jconrel.2014.04.009_bb0115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1472-9792(08)70024-6","article-title":"Rifampin","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.jconrel.2014.04.009_bb0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1472-9792(08)70008-8","article-title":"Ethambutol","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0125","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00396-004-1181-5","article-title":"Behavior of rifampicin in association with \u03b2-cyclodextrin in aqueous media: a spectroscopic and conductometric study","volume":"283","author":"Mehta","year":"2005","journal-title":"Colloid Polym. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2014.04.009_bb0130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1472-9792(08)70027-1","article-title":"Streptomycin","volume":"88","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(04)15496-2","article-title":"Programmes and principles in treatment of multidrug-resistant tuberculosis","volume":"363","author":"Mukherjee","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0140","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1128\/CMR.16.3.463-496.2003","article-title":"Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence","volume":"16","author":"Smith","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0145","first-page":"12","article-title":"Effects of isoniazid and pyrazinamide on bioavailability of rifampicin when co-administered rifampicin\u2013isoniazid\u2013pyrazinamide","volume":"36","author":"Luyen","year":"2005","journal-title":"TTC Nghien Cuu Y Hoc"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0150","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1208\/pt0803068","article-title":"A novel solid dosage form of rifampicin and isoniazid with improved functionality","volume":"8","author":"Gohel","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0378-5173(92)90355-6","article-title":"Kinetics for degradation of rifampicin, an azomethine containing drug which exhibits reversible hydrolysis in acidic solutions","volume":"78","author":"Prankerd","year":"1992","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10601330500533990","article-title":"Positioning of rifampicin in the Biopharmaceutics Classification System (BCS)","volume":"23","author":"Mariappan","year":"2006","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2013.02.012","article-title":"Encapsulation of rifampicin in a solid lipid nanoparticulate system to limit its degradation and interaction with isoniazid at acidic pH","volume":"446","author":"Singh","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-5173(99)00286-0","article-title":"Stability of rifampicin in dissolution medium in presence of isoniazid","volume":"190","author":"Shishoo","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1211\/146080800128736277","article-title":"The reason for increase in decomposition of rifampicin in the presence of isoniazid under acid conditions","volume":"6","author":"Singh","year":"2000","journal-title":"Pharm. Pharmacol. Commun."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0180","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1211\/146080800128735575","article-title":"Degradation of rifampicin, isoniazid, and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions","volume":"6","author":"Singh","year":"2000","journal-title":"Pharm. Pharmacol. Commun."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0185","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0378-5173(01)00831-6","article-title":"Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation","volume":"228","author":"Shishoo","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0190","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1081\/DDC-120021772","article-title":"Behaviour of decomposition of rifampicin in the presence of isoniazid in the pH range 1\u20133","volume":"29","author":"Sankar","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.blo.0000175887.98112.fe","article-title":"Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria","author":"Schatz","year":"2005","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1567201043334669","article-title":"Polymer based drug delivery systems for mycobacterial infections","volume":"1","author":"Pandey","year":"2004","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0205","doi-asserted-by":"crossref","first-page":"100","DOI":"10.18433\/J3M59P","article-title":"Present status of nanoparticle research for treatment of tuberculosis","volume":"14","author":"Shegokar","year":"2011","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0210","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17425247.4.6.621","article-title":"Advances and challenges of nanotechnology-based drug delivery systems","volume":"4","author":"Jiang","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0215","first-page":"169","article-title":"Computation of release kinetics of isoniazid microcapsules","volume":"130","author":"Muhuri","year":"1991","journal-title":"Boll. Chim. Farm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0220","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/03639049809082719","article-title":"Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches","volume":"24","author":"Jain","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0041-3879(91)90038-T","article-title":"Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer","volume":"72","author":"Gangadharam","year":"1991","journal-title":"Tubercle"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0230","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/33.2.273","article-title":"Bioavailability and chemotherapeutic activity of clofazimine against Mycobacterium avium complex infection in beige mice following a single implant of a biodegradable polymer","volume":"33","author":"Kailasam","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jac\/33.2.265","article-title":"Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers","volume":"33","author":"Gangadharam","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0240","first-page":"515","article-title":"Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide","volume":"3","author":"Gangadharam","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0245","first-page":"887","article-title":"Poly (d, l-lactide-co-glycolide) microparticles as carriers for antimycobacterial drug rifampicin","volume":"38","author":"Dutt","year":"2000","journal-title":"Indian J. Exp. Biol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0250","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/47.6.829","article-title":"Chemotherapy of Mycobacterium tuberculosis infections in mice by combination of isoniazid and rifampicin drugs entrapped in poly (d, l-lactide-co-glycolide) microparticles","volume":"47","author":"Dutt","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0255","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/03639049809085622","article-title":"A stable multiple emulsion system bearing isoniazid: preparation and characterization","volume":"24","author":"Khopade","year":"1998","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0260","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1128\/AAC.42.10.2682","article-title":"Use of microsphere technology for sustained and targeted delivery of rifampin to Mycobacterium tuberculosis-infected mice","volume":"42","author":"Barrow","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0265","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.43.5.1144","article-title":"Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice","volume":"43","author":"Quenelle","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0270","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0378-5173(02)00034-0","article-title":"Role of poly [dl-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s)","volume":"239","author":"Ain","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0275","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1128\/AAC.47.9.3005-3007.2003","article-title":"Chemotherapeutic potential of orally administered poly(lactide-co-glycolide) microparticles containing isoniazid, rifampicin and pyrazinamide against experimental tuberculosis","volume":"47","author":"Ain","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0285","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/ja.2011.58","article-title":"Recent advances in materials for extended-release antibiotic delivery system","volume":"64","author":"Gao","year":"2011","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0290","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2007.05.062","article-title":"Encapsulation of moxifloxacin within poly (butylcyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis","volume":"345","author":"Kisich","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11094-008-0073-2","article-title":"Development of a nanosomal formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate)","volume":"42","author":"Shipulo","year":"2008","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0300","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly (dl-lactide-coglycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"Pandey","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.08.017","article-title":"Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages","volume":"269","author":"Vyas","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0310","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","article-title":"Solid lipid nanoparticles for parenteral drug delivery","volume":"56","author":"Wissing","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tube.2004.11.003","article-title":"Solid lipid particle based inhalable sustained drug delivery system against experimental tuberculosis","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10965-008-9197-z","article-title":"Polymeric micelle composed of PLA and chitosan as a drug carrier","volume":"16","author":"Yan","year":"2009","journal-title":"J. Polym. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0325","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4314\/tjpr.v6i4.14665","article-title":"Preparation of polymeric micelles for use as carriers of tuberculostatic drugs","volume":"6","author":"Silva","year":"2007","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0330","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/1521-4184(200106)334:6<189::AID-ARDP189>3.0.CO;2-6","article-title":"Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)\u2013poly(aspartic acid) prodrug with isoniazid","volume":"334","author":"Silva","year":"2001","journal-title":"Arch. Pharm. Pharm. Med. Chem."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0335","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ardp.200500039","article-title":"Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug","volume":"339","author":"Silva","year":"2006","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/156720107779314794","article-title":"PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug","volume":"4","author":"Kumar","year":"2007","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0345","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1080\/10611860600825159","article-title":"Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers","volume":"14","author":"Kumar","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0350","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1128\/AAC.06049-11","article-title":"Targeted intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles","volume":"56","author":"Clemens","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijpharm.2009.10.004","article-title":"Gelatin nanocarriers as potential vectors for effective management of tuberculosis","volume":"385","author":"Saraogi","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0360","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijantimicag.2007.10.017","article-title":"Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles","volume":"31","author":"Ahmad","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11095-007-9355-8","article-title":"Incorporation of antitubercular drug isoniazid in pharmaceutically accepted microemulsion: effect on microstructure and physical parameters","volume":"25","author":"Mehta","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0370","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/45.1.77","article-title":"Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection","volume":"45","author":"Peters","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0375","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0378-5173(02)00261-2","article-title":"Rifampicin microparticles production by supercritical antisolvent precipitation","volume":"243","author":"Reverchon","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-8446(02)00162-6","article-title":"Micronization of antibiotics by supercritical assisted atomization","author":"Reverchon","year":"2003","journal-title":"J. Supercrit. Fluids"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0385","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.addr.2009.11.023","article-title":"New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery","volume":"62","author":"Sosnik","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0390","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/AAC.45.1.363-366.2001","article-title":"Therapeutic efficacy of poly (d, l-lactide-coglycolide) encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice","volume":"45","author":"Dutt","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0395","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jac\/47.6.829","article-title":"Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in poly (dl-lactide-co-glycolide) microparticles","volume":"47","author":"Dutt","year":"2001","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tube.2010.03.005","article-title":"The near future: improving the activity of rifamycins and pyrazinamide","volume":"90","author":"Mitchison","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0405","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.addr.2006.07.009","article-title":"Clinical perspectives on pulmonary systemic and macromolecular delivery","volume":"58","author":"Scheuch","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1773-2247(04)50020-5","article-title":"Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat","volume":"14","author":"Mullaicharam","year":"2004","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0415","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tube.2003.07.001","article-title":"Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis","volume":"83","author":"Pandey","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1010061013365","article-title":"Nanoparticles as antituberculosis drugs carriers: effect on activity against M. tuberculosis in human monocyte-derived macrophages","volume":"2","author":"Anisimova","year":"2000","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0425","unstructured":"I.P. Kaur, H. Singh, Preparation of solid lipid nanoparticles of rifampicin to improve bioavailability and limiting drug interaction with isoniazid, India Patent, 17\/01\/2013, 2013."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0430","unstructured":"I.P. Kaur, R. Bhandari, Solid lipid nanoparticles entrapping hydrophilic\/amphiphilic drug and a process for preparing the same. PCT\/IN2012\/000154. Dated 5\/03\/2012"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0435","unstructured":"I.P. Kaur, M.K. Verma, Oral nanocolloidal aqueous dispersion (NCD) of streptomycin sulfate, India Patent, 3\/10\/2012."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0440","series-title":"BIOOMAT 2009, I Workshop on Artificial Organs","article-title":"Synthesis and characterization of amphiphilic poly\/epsilon-caprolactone)-poly(ethyleneglycol) block copolymers. Optimization of the solubility and stability of rifampicin by means of encapsulation into polymeric micelles","author":"Moretton","year":"2009"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0445","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1016\/j.polymer.2007.06.003","article-title":"Injectable hydrogels of poly(\u03b5-caprolactone-coglycolide)\u2013poly(ethylene glycol)\u2013poly(\u03b5-caprolactone-co glycolide) triblock copolymer aqueous solutions","volume":"48","author":"Jiang","year":"2007","journal-title":"Polymer"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0450","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.2165\/00003495-200565170-00002","article-title":"Tuberculosis vaccines: current progress","volume":"65","author":"Orme","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0455","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tvjl.2004.11.001","article-title":"Progress in the development of vaccines and diagnostic reagents to control tuberculosis in cattle","volume":"171","author":"Vordermeier","year":"2006","journal-title":"Vet. J."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0460","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1128\/IAI.70.7.3681-3688.2002","article-title":"Improved tuberculosis DNA vaccines by formulation in cationic lipids","volume":"70","author":"D'Souza","year":"2002","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0465","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejpb.2006.10.014","article-title":"Development and bioavailability assessment of ramipril nanoemulsion formulation","volume":"66","author":"Shafiq","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0470","first-page":"812","article-title":"Effect of labrasol on self-nanoemulsification efficiency of ramipril nanoemulsion","volume":"64","author":"Shafiq","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0475","first-page":"806","article-title":"Potential of nanoemulsions for intravenous delivery of rifampicin","volume":"63","author":"Ahmed","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0480","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12249-009-9356-5","article-title":"Tween-embedded microemulsions\u2014physicochemical and spectroscopic analysis for antitubercular drugs","volume":"11","author":"Mehta","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0485","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/AAC.34.6.967","article-title":"Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice","volume":"34","author":"Klemens","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0490","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0495","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1128\/AAC.40.11.2618","article-title":"Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin","volume":"40","author":"Duzgunes","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0500","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.42.2.459","article-title":"Rationale for and efficacy of prolonged-interval treatment using liposome-encapsulated amikacin in experimental Mycobacterium avium infection","volume":"42","author":"Leitzke","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0505","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1128\/AAC.41.6.1211","article-title":"Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice","volume":"41","author":"Deol","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0510","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0304-4165(96)00088-8","article-title":"Lung specific liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice","volume":"1334","author":"Deol","year":"1997","journal-title":"Biochem. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0515","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/AAC.37.12.2584","article-title":"In vitro activities of free and liposomal drugs against Mycobacterium avium\u2013M. intracellulare complex and Mycobacterium tuberculosis","volume":"37","author":"Mehta","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0520","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/AAC.43.7.1638","article-title":"Effective treatment of acute and chronic murine tuberculosis with liposome encapsulated clofazimine","volume":"43","author":"Adams","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0525","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.09.017","article-title":"Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis","volume":"330","author":"El-Ridy","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijantimicag.2007.08.008","article-title":"Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis","volume":"31","author":"Gaspar","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0535","first-page":"1","article-title":"Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases","volume":"3","author":"Smola","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0540","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/02652049509087252","article-title":"Preparation and characterization of niosomes containing rifampicin for lung targeting","volume":"12","author":"Jain","year":"1995","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0545","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4103\/0250-474X.29622","article-title":"Niosomal system for delivery of rifampicin to lymphatics","volume":"68","author":"Jain","year":"2006","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0550","first-page":"1152","article-title":"Targeted delivery of rifampicin by niosomal drug delivery system","volume":"3","author":"Singh","year":"2010","journal-title":"JPR"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0555","first-page":"224","article-title":"Preparation, characterization and tissue disposition of niosomes containing isoniazid","volume":"2","author":"Karki","year":"2008","journal-title":"Rasayan J. Chem."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0560","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tube.2003.08.016","article-title":"Direct lung delivery of para-aminosalicylic acid by aerosol particles","volume":"83","author":"Tsapis","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0565","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3109\/03639040903410300","article-title":"Targeted drug delivery of rifampicin to the lungs: formulation, characterization, and stability studies of preformed aerosolized liposome and in situ formed aerosolized liposome","volume":"36","author":"Gaur","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0570","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","article-title":"Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model","volume":"51","author":"Garcia-Contreras","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)00324-X","article-title":"Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery","volume":"116","author":"Brannon-Peppas","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0580","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"Owens","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0585","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.nano.2010.02.002","article-title":"In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems","volume":"6","author":"Semete","year":"2010","journal-title":"Nanomed. Nanotechnol. Biol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0590","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ijantimicag.2004.07.010","article-title":"Chemotherapeutic efficacy of poly (d, l-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental","volume":"24","author":"Sharma","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0595","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jac\/dkh411","article-title":"Lectin functionalized poly (lactide-coglycolide) nanoparticles as oral\/aerosolized antitubercular drug carriers for treatment of tuberculosis","volume":"54","author":"Sharma","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0600","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.addr.2003.10.015","article-title":"The lectin\u2013cell interaction and its implications to intestinal lectin-mediated drug delivery","volume":"56","author":"Gabor","year":"2004","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0962-8479(97)90026-5","article-title":"rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo","volume":"78","author":"Johnson","year":"1997","journal-title":"Tuber. Lung Dis."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0610","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2008.11.027","article-title":"One step preparation of rifampicin\/poly (lactic-coglycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis","volume":"135","author":"Ohashi","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0615","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jac\/dkh260","article-title":"Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model","volume":"54","author":"Pandey","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0620","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijantimicag.2005.12.009","article-title":"Pharmacokinetic and pharmacodynamic behavior of antitubercular drugs encapsulated in alginate nanoparticles at two doses","volume":"27","author":"Zahoor","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0625","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1208\/s12249-007-9016-6","article-title":"Formulation and evaluation of a salted-out isoniazid-loaded nanosystem","volume":"9","author":"du Toit","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0630","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jac\/dkl128","article-title":"Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model","volume":"57","author":"Pandey","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0635","first-page":"49","article-title":"Potential of treating tuberculosis with a polymeric nano-drug delivery system","volume":"138","author":"Swai","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0640","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/713817583","article-title":"Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization","volume":"19","author":"Jenning","year":"2002","journal-title":"J. Microencapsulation"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0645","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbiotec.2004.06.007","article-title":"Challenges and solutions for the delivery of biotech drugs\u2014a review of drug nanocrystal technology and lipid nanoparticles","volume":"113","author":"Muller","year":"2004","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i1.10","article-title":"Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles","volume":"21","author":"Bummer","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0655","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00007691-198603000-00004","article-title":"Pharmacokinetics of rifampin in children II. Oral bioavailability","volume":"8","author":"Koup","year":"1986","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0660","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejpb.2007.03.022","article-title":"Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs","volume":"66","author":"Chiappetta","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0665","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11051-006-9103-8","article-title":"Enantiomeric PLA-PEG block copolymers and their stereocomplex micelles used as rifampin delivery","volume":"9","author":"Chen","year":"2007","journal-title":"J. Nanoparticle Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0670","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10965-008-9197-z","article-title":"Polymeric micelle composed of PLA and chitosan as a drug carrier","volume":"16","author":"Wu","year":"2009","journal-title":"J. Polym. Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0675","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.colsurfb.2008.01.023","article-title":"Monolayers of the lipid derivatives of isoniazid at the air\/water interface and the formation of self-assembled nanostructures in water","volume":"64","author":"Jin","year":"2008","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0680","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.progpolymsci.2005.01.007","article-title":"Birth of new molecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry","volume":"30","author":"Tomalia","year":"2005","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0685","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.addr.2005.09.012","article-title":"Dendrimer\u2013drug interactions","volume":"57","author":"Emanuele","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0690","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-5173(02)00623-3","article-title":"The influence of surface modification on the cytotoxicity of PAMAM dendrimers","volume":"252","author":"Jevprasesphant","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0695","first-page":"215","article-title":"Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis","volume":"10","author":"Katti","year":"2004","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0700","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1016\/j.fct.2011.08.006","article-title":"Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain","volume":"49","author":"Kakkar","year":"2011","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0705","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/rej.2011.1193","article-title":"Delivery of sesamol loaded solid lipid nanoparticles to brain for menopause related emotional and cognitive central nervous system derangements","volume":"14","author":"Kakkar","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0710","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejpb.2013.02.005","article-title":"Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats","volume":"85","author":"Kakkar","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0715","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1016\/j.biomaterials.2004.10.025","article-title":"Conjugated poly (d, l-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles","volume":"26","author":"Tosi","year":"2005","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0720","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2174\/1381612043384826","article-title":"New technologies for drug delivery across the blood brain barrier","volume":"10","author":"Kabanov","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0725","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2012.11.042","article-title":"Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles","volume":"441","author":"Bhandari","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0730","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0735","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11904-010-0054-4","article-title":"New antituberculous drugs in development","volume":"7","author":"Lalloo","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0740","first-page":"527","article-title":"Polymeric colloidal systems containing ethionamide: preparation and physicochemical characterization","volume":"55","author":"Lopes","year":"2000","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0745","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/10717544.2010.509367","article-title":"Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis","volume":"18","author":"Kumar","year":"2011","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0750","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.nano.2007.05.001","article-title":"Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis","volume":"3","author":"Ahmad","year":"2007","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0755","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.femsle.2005.07.022","article-title":"In vitro and ex vivo antimycobacterial potential of azole drugs against M. tuberculosis H37Rv","volume":"251","author":"Ahmad","year":"2005","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0760","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1574-6968.2006.00350.x","article-title":"Azole antifungals as novel chemotherapeutic agents against murine tuberculosis","volume":"261","author":"Ahmad","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0765","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1574-6968.2006.00224.x","article-title":"The potential of azole antifungals against latent\/persistent tuberculosis","volume":"258","author":"Ahmad","year":"2006","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0770","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1440-1843.2010.01775.x","article-title":"Current development and future prospects in chemotherapy of tuberculosis","volume":"15","author":"Nuermberger","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0775","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1159\/000110009","article-title":"Nanoparticle-based oral drug delivery system for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model","volume":"53","author":"Pandey","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0780","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1208\/s12249-010-9415-y","article-title":"Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles","volume":"11","author":"Wang","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0785","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1747-0285.2009.00804.x","article-title":"Fullerene isoniazid conjugate\u2014a tuberculostat with increased lipophilicity: synthesis and evaluation of antimycobacterial activity","volume":"73","author":"Kumar","year":"2009","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0790","series-title":"Oral drug delivery system for azole, moxifloxacin and rifampicin","author":"Khuller","year":"2010"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0795","series-title":"Antimicrobial for targeting intracellular pathogens","author":"Horwitz","year":"2000"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0800","series-title":"Particulate composition","author":"Dickinson","year":"2006"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0805","series-title":"Rifabutin-based medicinal agent, nanoparticles-containing antimicrobial preparation and a method for the production thereof","author":"Barsegyan","year":"2008"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0810","series-title":"Colloidal solid lipid vehicle for pharmaceutical use","author":"Schwarz","year":"2006"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0815","series-title":"Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution","author":"Becker","year":"1999"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0820","series-title":"Formulation solubilizing water-insoluble agents and preparation method thereof","author":"Jeong","year":"2006"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0825","series-title":"Nanodispersion of poorly water soluble drug(s)","author":"Chandavarkar","year":"2013"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0830","first-page":"491","article-title":"Tuberculosis-strategies towards antiinfectives for a chronic disease","volume":"1","author":"Barry","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0835","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2011.07.002","article-title":"Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era","volume":"156","author":"Huh","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0840","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1073\/pnas.0802822105","article-title":"Rifamycins do not function by allosteric modulation of binding of Mg2+ to the RNA polymerase active center","volume":"105","author":"Feklistov","year":"2008","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0845","series-title":"Goodman and Gillman's the Pharmacological Basis of Therapeutics","first-page":"1219","author":"Chambers","year":"2005"},{"issue":"9761","key":"10.1016\/j.jconrel.2014.04.009_bb0850","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(10)61889-2","article-title":"High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial","volume":"377","author":"Martineau","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0855","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/IAI.57.3.840-844.1989","article-title":"Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages","volume":"57","author":"Crowle","year":"1989","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0860","first-page":"554","article-title":"Tuberculosis and vitamin D deficiency","volume":"50","author":"Sasidharan","year":"2002","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.jconrel.2014.04.009_bb0865","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1079\/BJN2003837","article-title":"Vitamin D in preventive medicine: are we ignoring the evidence?","volume":"89","author":"Zittermann","year":"2003","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0870","first-page":"17","article-title":"Synergistic action of vitamin D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria","author":"Anand","year":"2008","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0875","unstructured":"i.P. Kaur, M.K. Verma, A process for preparing solid lipid sustained release nanoparticles for delivery of vitamins, PCT\/IB2013\/050169 dated 9\/1\/2013."},{"key":"10.1016\/j.jconrel.2014.04.009_bb0880","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jpba.2013.12.011","article-title":"Development of a validated UPLC method for simultaneous estimation of both free and entrapped (in solid lipid nanoparticles) all-trans retinoic acid and cholecalciferol (vitamin D3) and its pharmacokinetic applicability in rats","volume":"91","author":"Kumar","year":"2014","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365914002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T18:42:23Z","timestamp":1597689743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365914002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":175,"alternative-id":["S0168365914002132"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.04.009","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanostructured drug delivery for better management of tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2014.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}